Prevention of bone loss in paraplegics over 2 years with alendronate

Zehnder, Yvonne; Risi, Simone; Michel, Dieter; Knecht, Hans; Perrelet, Romain; Kraenzlin, Marius; Zäch, Guido A; Lippuner, Kurt (2004). Prevention of bone loss in paraplegics over 2 years with alendronate. Journal of bone and mineral research, 19(7), pp. 1067-74. Hoboken, N.J.: Wiley-Blackwell 10.1359/JBMR.040313

Full text not available from this repository. (Request a copy)

To assess the effects of long-term treatment of bone loss with alendronate in a group of paraplegic men, 55 patients were evaluated in a prospective randomized controlled open label study that was 2 years in duration comparing alendronate and calcium with calcium alone. Bone loss was stopped at all cortical and trabecular infralesional sites (distal tibial epiphysis, tibial diaphysis, total hip) with alendronate 10 mg daily.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis

UniBE Contributor:

Perrelet, Romain and Lippuner, Kurt

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0884-0431

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:24

Last Modified:

12 Aug 2014 14:36

Publisher DOI:

10.1359/JBMR.040313

PubMed ID:

15176988

Web of Science ID:

000222191600003

URI:

https://boris.unibe.ch/id/eprint/37834 (FactScience: 211995)

Actions (login required)

Edit item Edit item
Provide Feedback